2026-01-19 The NDA of Grand Pharma’s Global Innovative RDC TLX591-CDx Is Accepted by the NMPA

2026-01-26 Grand Pharma 2025 Annual Highlights Review

2026-01-04 Grand Pharma’s Subsidiary Has Entered Into a Share Purchase Agreement to Acquire All Equity of Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd.

2025-12-30 The World’s First Adrenaline Nasal Spray Introduced by Grand Pharma for the Treatment of Severe Allergic Reactions Obtains Drug Registration Certificate

2025-12-24 Grand Pharma Introduces the World’s First Adrenaline Nasal Spray for the Treatment of Severe Allergic Reactions

2025-12-22 The Phase lll Study in China of Grand Pharma’s Global Innovative RDC TLX591-CDx Successfully Achieves the Primary Endpoint

2025-12-18 Grand Pharma’s Independently Developed, Blockbuster, Globally Innovative Radionuclide-Drug Conjugate, GPN01530, Has Been Approved for Clinical Trials in the United States

2025-12-09 The Phase II Clinical Trial in China of Grand Pharma’s Class 1 Innovative Traditional Chinese Medicine GPN01360 Successfully Reaches the Clinical Endpoint

2025-10-26 The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment

2025-10-09 The Registration Clinical Study Conducted in China of the Global Innovative Temperature-Sensitive Embolic Agent Has Completed All Patients Enrollment

2025-09-24 Grand Pharma’s Treprostinil Injection Has Been Granted a Drug Registration Certificate by NMPA

2025-09-11 Grand Pharma Invited to Attend the 2025 Hong Kong International Biotechnology Conference & Exhibition